VLDL-induced triglyceride accumulation in human macrophages is mediated by modulation of LPL lipolytic activity in the absence of change in LPL mass.
Mixed dyslipidemia of phenotype IIB is characterized by elevated levels of very low density lipoprotein (VLDL)-1 and VLDL-2 subfractions and of low density lipoprotein (LDL), which are associated with premature formation of atherosclerotic plaques, characterized by the presence of lipid-rich macrophage foam cells. Lipoprotein lipase (LPL) is a key factor in mediating macrophage lipid accumulation and foam-cell formation from native VLDL particles. The action of macrophage-derived LPL in the induction of intracellular lipid accumulation from triglyceride-rich lipoprotein (TRL) subfractions (VLDL-1, VLDL-2) is, however, indeterminate, as is the potential role of VLDL-1 and VLDL-2 in modulating macrophage LPL expression. We evaluated the role of LPL in the interaction of type IIB VLDL-1 and VLDL-2 with human macrophages. Both VLDL-1 and VLDL-2 subfractions induced significant accumulation of triglyceride (9.8-fold, P<0.0001, and 4.8-fold, P<0.0001, respectively) and of free cholesterol content (1.4-fold, P<0.001, and 1.2-fold, P=0.02, respectively). Specific inhibition (90%) of the lipolytic activity of endogenous LPL by tetrahydrolipstatin (THL) in the presence of VLDL-1 or VLDL-2 resulted in marked reduction in cellular loading of both triglycerides (-89%, P=0.008, and -89%, P=0.015, respectively) and free cholesterol (-76%, P=0.02, and -55%, P=0.06 respectively). Furthermore, VLDL-1 and VLDL-2 induced marked increase in macrophage-derived LPL enzyme activity (+81%, P=0.002, and +45%, P=0.02), but did not modulate macrophage-derived LPL mRNA and protein expression; consequently, LPL specific activity was significantly increased from 1.6 mU/microg at baseline to 4.1 mU/microg (P=0.01) and 3.1 mU/microg (P=0.05), in the presence of VLDL-1 and VLDL-2, respectively. We conclude that type IIB VLDL-1 and VLDL-2 induce triglyceride accumulation in human monocyte-macrophages primarily via the lipolytic action of LPL, which may involve stabilization and activation of the macrophage-secreted enzyme, rather than via modulation of enzyme production.
Milosavljevic
Dragana
D
National Institute for Health and Medical Research (INSERM) Unite 551, Hôpital de la Pitié, 83, Boulevard de l'Hôpital, F-75651 Paris Cedex 13, France.
Kontush
Anatol
A
Griglio
Sabine
S
Le Naour
Gilles
G
Thillet
Joëlle
J
Chapman
M John
MJ
D002478:Cells, Cultured; D002784:Cholesterol / Q000032:analysis / Q000378:metabolism / Q000494:pharmacology; D004789:Enzyme Activation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005487:Foam Cells / Q000378:metabolism; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood*; D007783:Lactones / Q000494:pharmacology; D008066:Lipolysis; D008071:Lipoprotein Lipase / Q000032:analysis / Q000037:antagonists & inhibitors / Q000378:metabolism*; D008074:Lipoproteins / Q000494:pharmacology; D008079:Lipoproteins, VLDL / Q000097:blood* / Q000737:chemistry / Q000302:isolation & purification; D008264:Macrophages / Q000378:metabolism*; D000077403:Orlistat; D012333:RNA, Messenger / Q000032:analysis; D014280:Triglycerides / Q000032:analysis / Q000378:metabolism
D004791:Enzyme Inhibitors; D007783:Lactones; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D012333:RNA, Messenger; D014280:Triglycerides; C030104:lipoprotein cholesterol; D000077403:Orlistat; D002784:Cholesterol; D008071:Lipoprotein Lipase